A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
ME Dudley, JR Wunderlich, JC Yang… - Journal of …, 2002 - journals.lww.com
This report describes a phase I clinical trial using nonmyeloablative, lympho-depleting
chemotherapy in combination with adoptive immunotherapy in patients with metastatic
melanoma. The chemotherapy-conditioning schedule that induced transient lymphopenia
consisted of cyclophosphamide (30 or 60 mg/kg per day for 2 days) followed by fludarabine
(25 mg/m 2 per day for 5 days). Immunotherapy for all patients consisted of in vitro
expanded, tumor-reactive, autologous T-cell clones selected for high avidity recognition of …
chemotherapy in combination with adoptive immunotherapy in patients with metastatic
melanoma. The chemotherapy-conditioning schedule that induced transient lymphopenia
consisted of cyclophosphamide (30 or 60 mg/kg per day for 2 days) followed by fludarabine
(25 mg/m 2 per day for 5 days). Immunotherapy for all patients consisted of in vitro
expanded, tumor-reactive, autologous T-cell clones selected for high avidity recognition of …